Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read More
Tag: recurrence
Molecular patterns could better predict breast cancer recurrence
A study has found that molecular patterns could better predict breast cancer recurrence.
Read More
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used by the NHS post surgery to prevent breast cancer recurrence.
Read More
BMS’ Opdivo cuts risk of melanoma recurrence
Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning.
Read More
- R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
- Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
- Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
- ViiV Healthcare to unveil new HIV treatment data at AIDS 2026
- Jasper Therapeutics merges with Kira Pharmaceuticals
